# Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients

> **NCT01820962** · PHASE3 · TERMINATED · sponsor: **Maastricht University Medical Center** · enrollment: 212 (actual)

## Conditions studied

- Hematological Malignancies
- Bacteremia
- Thrombosis

## Interventions

- **PROCEDURE:** heparin
- **PROCEDURE:** concentrated citrate

## Key facts

- **NCT ID:** NCT01820962
- **Lead sponsor:** Maastricht University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-07
- **Primary completion:** 2010-12
- **Final completion:** 2012-07
- **Target enrollment:** 212 (ACTUAL)
- **Why stopped:** Because the inclusion rate was lower than expected.
- **Last updated:** 2013-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01820962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01820962, "Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01820962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*